What is CNS Pharmaceuticals's earnings per share (EPS)?

CNS Pharmaceuticals (CNSP) reported diluted earnings per share of $-35.75 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CNS Pharmaceuticals Financials

CNSP

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows CNS Pharmaceuticals (CNSP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CNSP FY2025 2026-04-30

External financing rather than operations supports a research-heavy cash-burn model with almost no fixed-asset investment.

FY2023 ended with negative equity and only $549K of cash, but FY2024 financing rebuilt liquidity. FY2025 still used $13.8M in operating cash against an ending cash balance of $7.2M, so the repair did not make the business self-funding; it mainly bought time for another year of research spending.

Cash burn mirrors the income statement: FY2025 operating cash outflow was $13.8M while net loss was $15.9M. With capex at just $18K, this is an expense-funded model where cash leaves through research and overhead, not through building hard assets.

Balance-sheet flexibility narrowed in FY2025 even after the prior recapitalization: the current ratio ended at 2.0x and total liabilities reached $4.1M. With no long-term debt reported, funding pressure comes less from lenders than from the need to keep replacing burned cash with new external capital on a recurring basis for operating needs.

Financial Health Signals

Financial Profile 20/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of CNS Pharmaceuticals's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

CNS Pharmaceuticals carries a low D/E ratio of 0.91, meaning only $0.91 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 84/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

CNS Pharmaceuticals's current ratio of 1.98 indicates adequate short-term liquidity, earning a score of 36/100. The company can meet its near-term obligations, though with limited headroom.

Returns

CNS Pharmaceuticals generates a -350.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -240.6% the prior year.

Piotroski F-Score Weak

1/9

CNS Pharmaceuticals passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.87x

For every $1 of reported earnings, CNS Pharmaceuticals generates $0.87 in operating cash flow (-$13.8M OCF vs -$15.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1049.7x

CNS Pharmaceuticals earns $-1049.7 in operating income for every $1 of interest expense (-$16.0M vs $15K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$16.0M

YoY-7.3%

CNS Pharmaceuticals's EBITDA was -$16.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.3% from the prior year.

Net Income

-$15.9M

YoY-6.7%

CNS Pharmaceuticals reported -$15.9M in net income in fiscal year 2025. This represents a decrease of 6.7% from the prior year.

EPS (Diluted)

$-35.75

CNS Pharmaceuticals earned $-35.75 per diluted share (EPS) in fiscal year 2025. This represents an increase of 92.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$13.8M

YoY+19.2%

CNS Pharmaceuticals generated -$13.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 19.2% from the prior year.

Cash & Debt

$7.2M

YoY+11.4%

5Y CAGR-12.5%

CNS Pharmaceuticals held $7.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

632,516

CNS Pharmaceuticals had 632,516 shares outstanding in fiscal year 2025. This represents an increase of 437.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-350.5%

YoY-109.9pp

5Y CAGR-282.7pp

CNS Pharmaceuticals's ROE was -350.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 109.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$9.8M

YoY+5.2%

5Y CAGR+14.1%

CNS Pharmaceuticals invested $9.8M in research and development in fiscal year 2025. This represents an increase of 5.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$18K

YoY+334.0%

5Y CAGR+0.3%

CNS Pharmaceuticals invested $18K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 334.0% from the prior year.

CNSP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9.8M+5.2%	$9.3M	N/A	$9.3M-5.2%	$9.8M+93.7%	$5.1M
SG&A Expenses	$6.2M+10.7%	$5.6M+17.7%	$4.8M-20.1%	$6.0M+27.5%	$4.7M+6.6%	$4.4M
Operating Income	-$16.0M-7.3%	-$14.9M	N/A	-$15.3M-5.4%	-$14.5M-53.2%	-$9.5M
Interest Expense	$15K-5.5%	$16K+16.8%	$14K+96.5%	$7K-24.3%	$9K+184.5%	$3K
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$15.9M-6.7%	-$14.9M	N/A	-$15.3M-5.4%	-$14.5M-53.3%	-$9.5M
EPS (Diluted)	$-35.75	$-466.89	$-12509.11	$-11.22+32.0%	$-16.50	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$2.2M+88.2%	$1.2M-64.0%	$3.2M	N/A	$4.2M+280.2%	$1.1M-54.1%	$2.4M
SG&A Expenses	N/A	$1.1M-15.0%	$1.2M+13.5%	$1.1M	N/A	$1.4M-2.0%	$1.4M+26.7%	$1.1M
Operating Income	N/A	-$3.3M-35.0%	-$2.4M+44.5%	-$4.3M	N/A	-$5.6M-122.7%	-$2.5M+28.7%	-$3.5M
Interest Expense	N/A	$2K-49.4%	$4K-32.6%	$6K	N/A	$2K-49.4%	$4K-32.6%	$7K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$3.2M-35.5%	-$2.4M+44.8%	-$4.3M	N/A	-$5.6M-121.5%	-$2.5M+28.6%	-$3.5M
EPS (Diluted)	N/A	$-5.76+10.3%	$-6.42	$-1.58	N/A	$-153.20+96.2%	$-4049.20	$-1020.48

CNSP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$8.6M-0.9%	$8.7M+411.6%	$1.7M-87.0%	$13.1M+49.1%	$8.8M-44.8%	$15.9M
Current Assets	$8.1M-6.4%	$8.7M+444.2%	$1.6M-87.3%	$12.6M+68.0%	$7.5M-51.7%	$15.5M
Cash & Equivalents	$7.2M+11.4%	$6.5M+1077.5%	$549K-94.5%	$10.1M+100.9%	$5.0M-64.4%	$14.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.1M+62.5%	$2.5M-58.8%	$6.1M+24.6%	$4.9M+89.7%	$2.6M+36.1%	$1.9M
Current Liabilities	$4.1M+62.5%	$2.5M-58.8%	$6.1M+24.6%	$4.9M+89.7%	$2.6M+36.1%	$1.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.5M-26.8%	$6.2M+239.4%	-$4.4M-154.5%	$8.1M+32.0%	$6.2M-55.8%	$13.9M
Retained Earnings	-$100.3M-18.8%	-$84.4M-21.4%	-$69.6M-37.2%	-$50.7M-43.1%	-$35.4M-69.2%	-$20.9M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$8.6M-27.3%	$11.9M-18.2%	$14.5M+5.5%	$13.7M+58.0%	$8.7M+17.4%	$7.4M+200.1%	$2.5M+48.7%	$1.7M
Current Assets	$8.1M-28.9%	$11.4M-19.4%	$14.1M+3.0%	$13.7M+58.5%	$8.7M+17.2%	$7.4M+244.4%	$2.1M+34.0%	$1.6M
Cash & Equivalents	$7.2M-27.0%	$9.9M-18.7%	$12.1M-7.0%	$13.0M+101.9%	$6.5M-7.3%	$7.0M+367.5%	$1.5M+83.0%	$815K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.1M+109.3%	$2.0M+41.7%	$1.4M-50.2%	$2.8M+10.1%	$2.5M-37.8%	$4.1M-40.0%	$6.8M+11.0%	$6.1M
Current Liabilities	$4.1M+109.3%	$2.0M+41.7%	$1.4M-50.2%	$2.8M+10.1%	$2.5M-37.8%	$4.1M-40.0%	$6.8M+11.0%	$6.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.5M-54.4%	$9.9M-24.5%	$13.1M+19.6%	$11.0M+77.6%	$6.2M+84.2%	$3.4M+178.1%	-$4.3M+3.1%	-$4.4M
Retained Earnings	-$100.3M-6.3%	-$94.3M-3.5%	-$91.1M-2.7%	-$88.7M-5.1%	-$84.4M-3.9%	-$81.2M-7.4%	-$75.6M-3.5%	-$73.1M

CNSP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$13.8M+19.3%	-$17.1M	N/A	-$10.6M+22.0%	-$13.5M-85.0%	-$7.3M
Capital Expenditures	$18K+334.0%	$4K+7.4%	$4K-11.8%	$4K-23.1%	$6K-68.0%	$18K
Free Cash Flow	-$13.8M+19.2%	-$17.1M	N/A	-$10.6M+22.0%	-$13.5M-84.6%	-$7.3M
Investing Cash Flow	-$18K-334.0%	-$4K-7.4%	-$4K+11.8%	-$4K+23.1%	-$6K+68.0%	-$18K
Financing Cash Flow	$14.6M-36.7%	$23.0M+396.6%	$4.6M-70.3%	$15.6M+246.3%	$4.5M-68.1%	$14.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$3.1M-40.4%	-$2.2M+59.3%	-$5.3M-64.8%	-$3.2M+40.7%	-$5.5M+19.5%	-$6.8M-312.0%	-$1.7M+48.3%	-$3.2M
Capital Expenditures	N/A	N/A	N/A	N/A	$4K	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	-$5.5M	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	-$4K	N/A	N/A	N/A
Financing Cash Flow	$407K+544.1%	-$92K-102.1%	$4.4M-55.0%	$9.8M+98.0%	$5.0M-59.6%	$12.3M+427.8%	$2.3M-32.7%	$3.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CNSP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-350.5%-109.9pp	-240.6%	N/A	-187.8%+47.4pp	-235.2%-167.4pp	-67.8%
Return on Assets	-183.8%-13.1pp	-170.8%	N/A	-117.0%+48.5pp	-165.5%-105.9pp	-59.7%
Current Ratio	1.98-1.5	3.43+3.2	0.26-2.3	2.55-0.3	2.88-5.3	8.13
Debt-to-Equity	0.91+0.5	0.41+1.8	-1.38-2.0	0.60+0.2	0.42+0.3	0.14
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-32.5%-14.4pp	-18.1%+21.1pp	-39.2%	N/A	-167.2%	N/A	N/A
Return on Assets	N/A	-27.1%-10.7pp	-16.4%+14.9pp	-31.3%	N/A	-75.7%+26.8pp	-102.5%+110.9pp	-213.4%
Current Ratio	1.98-3.8	5.81-4.4	10.22+5.3	4.94+1.5	3.43+1.6	1.82+1.5	0.32+0.1	0.26
Debt-to-Equity	0.91+0.7	0.20+0.1	0.11-0.1	0.25-0.2	0.41-0.8	1.21+2.8	-1.58-0.2	-1.37
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Quoin Pharmaceuticals Ltd QNRX

$11.6M

Oragenics OGEN

$2.7M

Jaguar Health Inc JAGX

$1.0M

THERIVA BIOLOGICS INC TOVX

$17.5M

Xenetic Biosciences Inc XBIO

$7.3M

Frequently Asked Questions

Is CNS Pharmaceuticals profitable?

No, CNS Pharmaceuticals (CNSP) reported a net income of -$15.9M in fiscal year 2025.

What is CNS Pharmaceuticals's EBITDA?

CNS Pharmaceuticals (CNSP) had EBITDA of -$16.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is CNS Pharmaceuticals's return on equity (ROE)?

CNS Pharmaceuticals (CNSP) has a return on equity of -350.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is CNS Pharmaceuticals's free cash flow?

CNS Pharmaceuticals (CNSP) generated -$13.8M in free cash flow during fiscal year 2025. This represents a 19.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is CNS Pharmaceuticals's operating cash flow?

CNS Pharmaceuticals (CNSP) generated -$13.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are CNS Pharmaceuticals's total assets?

CNS Pharmaceuticals (CNSP) had $8.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are CNS Pharmaceuticals's capital expenditures?

CNS Pharmaceuticals (CNSP) invested $18K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does CNS Pharmaceuticals spend on research and development?

CNS Pharmaceuticals (CNSP) invested $9.8M in research and development during fiscal year 2025.

How many shares does CNS Pharmaceuticals have outstanding?

CNS Pharmaceuticals (CNSP) had 632,516 shares outstanding as of fiscal year 2025.

What is CNS Pharmaceuticals's current ratio?

CNS Pharmaceuticals (CNSP) had a current ratio of 1.98 as of fiscal year 2025, which is generally considered healthy.

What is CNS Pharmaceuticals's debt-to-equity ratio?

CNS Pharmaceuticals (CNSP) had a debt-to-equity ratio of 0.91 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is CNS Pharmaceuticals's return on assets (ROA)?

CNS Pharmaceuticals (CNSP) had a return on assets of -183.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is CNS Pharmaceuticals's cash runway?

Based on fiscal year 2025 data, CNS Pharmaceuticals (CNSP) had $7.2M in cash against an annual operating cash burn of $13.8M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is CNS Pharmaceuticals's Piotroski F-Score?

CNS Pharmaceuticals (CNSP) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are CNS Pharmaceuticals's earnings high quality?

CNS Pharmaceuticals (CNSP) has an earnings quality ratio of 0.87x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can CNS Pharmaceuticals cover its interest payments?

CNS Pharmaceuticals (CNSP) has an interest coverage ratio of -1049.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is CNS Pharmaceuticals?

CNS Pharmaceuticals (CNSP) scores 20 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.